Literature DB >> 25696900

Caring for the long-term survivor after allogeneic stem cell transplantation.

Smita Bhatia1.   

Abstract

Survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk of developing long-term complications such as subsequent malignancies and cardiopulmonary compromise. The prevalence of chronic health conditions approaches 75% among allogeneic HCT survivors and that for severe or life-threatening conditions exceeds 20%. This chapter describes the burden of morbidity carried by HCT survivors to help healthcare providers and policy makers understand the scope of the problem and the need for life-long follow-up and proactive care for this vulnerable population.
© 2014 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25696900     DOI: 10.1182/asheducation-2014.1.495

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  6 in total

1.  Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes.

Authors:  A Hamblin; D M Greenfield; M Gilleece; N Salooja; M Kenyon; E Morris; N Glover; P Miller; H Braund; A Peniket; B E Shaw; J A Snowden
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

2.  Coming of Age With Cancer: Physical, Social, and Financial Barriers to Independence Among Emerging Adult Survivors

Authors:  Eden Brauer; Huibrie C Pieters; Patricia A Ganz; Wendy Landier; Carol Pavlish; MarySue V Heilemann
Journal:  Oncol Nurs Forum       Date:  2018-03-01       Impact factor: 2.172

3.  Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.

Authors:  Sonali Chaudhury; Rodney Sparapani; Zhen-Huan Hu; Taiga Nishihori; Hisham Abdel-Azim; Adriana Malone; Richard Olsson; Mehdi Hamadani; Andrew Daly; Ulrike Bacher; Baldeep M Wirk; Rammurti T Kamble; Robert P Gale; William A Wood; Gregory Hale; Peter H Wiernik; Shahrukh K Hashmi; David Marks; Celalettin Ustun; Reinhold Munker; Bipin N Savani; Edwin Alyea; Uday Popat; Ronald Sobecks; Matt Kalaycio; Richard Maziarz; Nobuko Hijiya; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2016-03-08       Impact factor: 5.742

4.  In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.

Authors:  Kentaro Minagawa; Muhammad O Jamil; Mustafa Al-Obaidi; Larisa Pereboeva; Donna Salzman; Harry P Erba; Lawrence S Lamb; Ravi Bhatia; Shin Mineishi; Antonio Di Stasi
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

Review 5.  Pathophysiology of GvHD and Other HSCT-Related Major Complications.

Authors:  Sakhila Ghimire; Daniela Weber; Emily Mavin; Xiao Nong Wang; Anne Mary Dickinson; Ernst Holler
Journal:  Front Immunol       Date:  2017-03-20       Impact factor: 7.561

6.  Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up.

Authors:  Maria Teresa Lupo-Stanghellini; Simona Piemontese; Andrea Assanelli; Fabio Serpenti; Sara Mastaglio; Daniela Clerici; Fabio Giglio; Raffaella Greco; Francesca Lorentino; Francesca Pavesi; Francesca Farina; Sarah Marktel; Consuelo Corti; Jacopo Peccatori; Fabio Ciceri
Journal:  Hemasphere       Date:  2021-10-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.